Another IPR denial for Bass

The U.S. Patent and Trademark Office denied an inter partes review (IPR) petition from Kyle Bass' Coalition for Affordable Drugs challenging a patent for Tecfidera dimethyl fumerate from Biogen Inc. (NASDAQ:BIIB) to treat multiple sclerosis (MS).

The USPTO's Patent Trials and Appeals Board (PTAB) disagreed that the prior art supplied by the coalition established that claims in U.S. Patent No. 8,399,514 were obvious. ...